Evotec Enters into Agreement with Pfizer

Evotec AG has announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis.

Under the terms of this licence and collaboration agreement, scientists at Evotec and Pfizer will explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec will contribute its drug discovery platform whereas Pfizer will provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise.

Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are proud about Pfizer partnering with us in our growing initiative in the fibrosis field utilizing one of our internal programmes."

Dr Charles MacKay, Chief Scientific Officer, Inflammation and Immunology at Pfizer, added: "We believe that Evotec's discovery platform is well-positioned to deliver potentially innovative approaches to several areas of tissue fibrosis. We are excited about the possibilities of this agreement."